Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.
Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.
Rapid Micro Biosystems announced the pricing of its initial public offering (IPO) of 7,920,000 shares of Class A common stock at $20.00 per share, aiming to raise $158.4 million before expenses. The shares will trade on the Nasdaq under the symbol RPID starting July 15, 2021, with the offering expected to close on July 19, 2021. Underwriters have a 30-day option to purchase an additional 1,188,000 shares. The company focuses on automation solutions for healthcare product manufacturing.